Praxis Precision Medicines, Inc. PRAX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Program-specific expenses by Product | ||||||
| Elsunersen | $9.27M+290% | $6.83M+220% | $4.85M-7.4% | $3.01M-64.6% | $2.38M-79.3% | |
| Other early stage assets | $10.16M+111% | $8.02M+73.0% | $7.06M+41.0% | $5.09M-8.9% | $4.82M-22.4% | |
| Relutrigine | $53.43M+402% | $45.95M+633% | $33.61M+645% | $19.91M+369% | $10.64M+166% | |
| Ulixacaltamide | $58.8M-27.9% | $63.21M-8.6% | $79.55M+65.6% | $87.89M+167% | $81.55M+217% | |
| Vormatrigine | $80.82M+158% | $74.06M+303% | $61.74M+473% | $47.46M+728% | $31.36M+477% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Praxis Precision Medicines, Inc. break its business down?
- Praxis Precision Medicines, Inc. (PRAX) reports program-specific expenses by product across 5 parts — Elsunersen, Other early stage assets, Relutrigine, Ulixacaltamide and Vormatrigine. Each is extracted from the segment footnotes and tracked over time.
- Where does Praxis Precision Medicines, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Praxis Precision Medicines, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.